VSV-02 Injection: VSV-02 Injection is an oncolytic virus vaccine based on an attenuated Vesicular Stomatitis Virus (VSV) that is engineered to encode a CD3/PD-L1 bispecific antibody. It is supplied as a sterile solution by Shanghai Rongrui Pharmaceutical Technology Co., Ltd., with a specification of 1 mL per vial and a viral titer of 3.0×10\^10 PFU/mL.
The investigational product is administered via two routes: intratumoral (IT) injection followed by intravenous (IV) infusion on Day 1 (D1) of each 21-day treatment cycle. Patients may receive up to 6 cycles of treatment.
In this dose-escalation study, participants are enrolled into predefined dose cohorts. The starting dose for the first cohort is 6×10\^10 PFU via intratumoral injection and 6×10\^11 PFU via intravenous infusion.
Study summary
This is a clinical study for patients with advanced solid tumors who have limited or no effective treatment options available. The study aims to evaluate a new investigational drug called VSV-02 Injection, which is developed by Shanghai Rongrui Pharmaceutical Technology Co., Ltd.
The main purpose of this open-label, single-arm study is to assess the preliminary effectiveness and safety of VSV-02 when it is given through two routes: directly into a vein (intravenously) and by injection directly into the tumor (intratumorally). Patients will receive the treatment on the first day of each 3-week cycle, for up to 6 cycles.
The study will follow a dose-escalation design to find a suitable dose. Treatment may be stopped if the disease progresses, if side effects become intolerable, or if the patient chooses to withdraw, among other reasons. Researchers will closely monitor patients to see if VSV-02 can help control the cancer and to record any side effects that may occur.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
Voluntary signed informed consent.
Age ≥ 18 years.
Histologically or cytologically confirmed advanced solid tumor (e.g., melanoma, head and neck squamous cell carcinoma, cervical cancer, osteosarcoma, nasopharyngeal carcinoma, breast cancer, lung cancer, colorectal cancer, liver cancer, gastric cancer).
Disease progression after at least two prior lines of standard therapy (including targeted therapy), or for whom no standard therapy exists or is medically unsuitable.
At least one measurable lesion per RECIST 1.1 criteria.
At least one lesion accessible for intratumoral injection.
ECOG performance status of 0-2.
Life expectancy ≥ 12 weeks.
Adequate organ and bone marrow function.
Negative pregnancy test for women of childbearing potential.
Agreement to use effective contraception during the study and for at least 6 months after the last dose.
Exclusion Criteria:
Symptomatic or untreated brain metastases (asymptomatic or stable for ≥3 months after local therapy allowed).
Radiotherapy to the target lesion within 2 months.
History of other active malignancy within 5 years (with specific exceptions).
Lesion intended for injection with a longest diameter \> 100 mm.
Participation in another interventional clinical trial within 4 weeks.
Prior or planned organ/tissue transplantation.
Active HIV, Hepatitis B, Hepatitis C, or Syphilis infection meeting specific criteria.
Requirement for concomitant antiviral or therapeutic anticoagulation.
Uncontrolled ≥ Grade 3 active infection.
Specific washout periods for prior anti-cancer therapies not met.
Uncontrolled cardiovascular disease.
Active or history of autoimmune disease (with specific exceptions).
Requirement for systemic corticosteroids (\>10 mg prednisone equivalent) within 14 days or during the study.
Tumors located in high-risk anatomical sites.
Administration of live vaccines during the study period.
Known hypersensitivity to any component of the study drug or related immunotherapies.
History of severe mental illness, substance abuse, or other conditions that may interfere with study compliance.
Pregnancy or lactation.
Toxicities from previous anti-cancer therapy not recovered to ≤ Grade 1 (except alopecia).
Any other condition deemed inappropriate for participation by the investigator.
Primary outcome measure(s)
Objective Response Rate (ORR) — From enrollment until the first occurrence of disease progression or the end of treatment, up to 24 months. ORR is defined as the proportion of participants achieving a best overall response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by the investigator.
Disease Control Rate (DCR) — From enrollment until the first occurrence of disease progression or the end of treatment, up to 24 months. DCR is defined as the proportion of participants achieving a best overall response of complete response (CR), partial response (PR), or stable disease (SD) (lasting for at least 6 weeks) per RECIST 1.1.
Duration of Response (DoR) — From the first objective response (CR or PR) until disease progression or death from any cause, assessed up to 36 months. DoR is defined as the time from the first documentation of CR or PR to the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first, as per RECIST 1.1.
Progression-Free Survival (PFS) — From enrollment until the first occurrence of disease progression or death from any cause, assessed up to 36 months. PFS is defined as the time from enrollment to the first documentation of progressive disease (PD) as per RECIST 1.1 or death from any cause, whichever occurs first.
verall Survival (OS) — From enrollment until death from any cause, assessed up to 60 months. OS is defined as the time from enrollment to death due to any cause.
Trial sites (1)
Facility
City
Region
Status
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang
Henan
Recruiting
More The First Affiliated Hospital of Xinxiang Medical College trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.